multiple PBS-reimbursed indications
Rheumatology · 2014–2014
1decision
1medicine
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| golimumab; infliximab; ustekinumab Amendment to authority requirements for continuing treatment with golimumab, infliximab, and ustekinumab for all PBS-reimbursed indications (including severe… | Jul 2014 | Deferred | input received |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.